AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased 38,000 additional company shares in the open market. This acquisition increases Cerrone's total holdings to 4,910,759 shares.

Positive

Chairman's increased stake demonstrates insider confidence in company
Significant insider ownership with Chairman holding 4.91M shares

Negative

Trading on OTCQB market indicates lower tier exchange listing

News Market Reaction 1 Alert

+0.04% News Effect

On the day this news was published, ACUT gained 0.04%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

04/10/2025 - 07:00 AM

LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 38,000 ACUT shares in the open market. This brings his total holding to 4,910,759 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.

Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com